V-Bio Ventures

Avidicure is a cancer care company focused on enhancing immune system function through innovative therapies. It is developing a novel antibody modality known as "AVC-Boosters," which are dual agonistic and multifunctional, engineered to deliver targeted and effective monotherapy. This approach aims to provide broad applicability in oncology, addressing various cancer types while prioritizing safety and efficacy. Currently, Avidicure is operating in stealth mode, indicating a focus on research and development before public engagement.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.

Flindr Therapeutics, a private biotech company develops next-generation precision oncology treatments.

Protealis specializes in developing advanced seeds and seed technologies for legume crops, focusing on enhancing their adaptability to the European environment. The company aims to become a leading provider of germplasm for sustainable plant proteins, leveraging innovative breeding techniques and nitrogen fixation. By utilizing proprietary seed coatings and advanced breeding technologies, Protealis seeks to maximize the potential of legume crops. This approach not only helps farmers address protein deficits but also supports local sourcing for the increasing demand from producers of meat and milk alternatives.

Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.

Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure.

Aphea.Bio focuses on developing innovative agricultural products aimed at enhancing crop health and yields. The company specializes in creating next-generation biopesticides derived from natural microorganisms, which serve as sustainable alternatives to traditional chemical pesticides facing regulatory challenges. Additionally, Aphea.Bio produces biostimulants that promote crop growth by enhancing nutrient uptake from the soil. Utilizing proprietary technologies, the company is dedicated to discovering new biocontrol and biostimulant products that help farmers sustainably manage fungal diseases, pests, and weeds, ultimately improving crop productivity and environmental health.

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Muna Therapeutics is a biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases, such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying new medicines that preserve cognitive function and enhance resilience against these debilitating conditions, thereby providing individuals affected by neurodegenerative diseases with access to effective treatment options. Through its innovative approach, Muna Therapeutics strives to improve the quality of life for those suffering from these challenging disorders.

Protealis specializes in developing advanced seeds and seed technologies for legume crops, focusing on enhancing their adaptability to the European environment. The company aims to become a leading provider of germplasm for sustainable plant proteins, leveraging innovative breeding techniques and nitrogen fixation. By utilizing proprietary seed coatings and advanced breeding technologies, Protealis seeks to maximize the potential of legume crops. This approach not only helps farmers address protein deficits but also supports local sourcing for the increasing demand from producers of meat and milk alternatives.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments to address various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technology aimed at improving the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular seeks to enhance therapeutic outcomes while minimizing side effects and reducing the frequency of treatments, thereby offering patients effective and life-changing solutions for their unmet medical needs.

Aphea.Bio focuses on developing innovative agricultural products aimed at enhancing crop health and yields. The company specializes in creating next-generation biopesticides derived from natural microorganisms, which serve as sustainable alternatives to traditional chemical pesticides facing regulatory challenges. Additionally, Aphea.Bio produces biostimulants that promote crop growth by enhancing nutrient uptake from the soil. Utilizing proprietary technologies, the company is dedicated to discovering new biocontrol and biostimulant products that help farmers sustainably manage fungal diseases, pests, and weeds, ultimately improving crop productivity and environmental health.

Animab is a biotechnology company focused on enhancing livestock health through innovative monoclonal antibody technology. By leveraging advanced research in animal science, Animab develops products that aim to improve animal welfare, reduce operational costs, and promote sustainability in livestock farming. Their proprietary antibodies are designed to mimic secretory IgA, a natural antibody found in colostrum and milk, which provides critical protection for piglets during the vulnerable post-weaning phase. These antibodies target specific intestinal pathogens while preserving the healthy microbiome, ensuring that piglets remain healthy and resilient during this crucial developmental period. Through its solutions, Animab seeks to benefit animals, producers, and consumers alike.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.

ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.

Orionis Biosciences is a biotechnology company focused on early-stage drug discovery and development, particularly targeting oncology and immunotherapies. Headquartered in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes a range of innovative technologies to create conditionally active drug modalities aimed at treating diseases with significant unmet medical needs. By inducing molecular proximity and cooperativity, Orionis enhances drug potency and precision, allowing for novel target access. Their approach facilitates the development of a diverse pipeline of drug candidates, including therapies that engage both adaptive and innate immune systems. The company collaborates with strategic partners, including VIB in Belgium, and is supported by a team of seasoned entrepreneurs and scientists, as well as a transatlantic network of investors.

RootWave is a company based in Kineton, United Kingdom, that specializes in developing and distributing innovative machinery for weed control in agricultural settings. Founded in 2012, the company offers hand weeders designed for growers, gardeners, and groundskeepers, as well as automated solutions that utilize visual recognition technology to effectively target and eliminate weeds in arable crops. RootWave's electric shock technology provides a chemical-free alternative to traditional herbicides, allowing users to manage invasive plants sustainably and economically. The company's products are marketed through distributors in various regions, including France, Australasia, Ireland, and South Korea.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Aphea.Bio focuses on developing innovative agricultural products aimed at enhancing crop health and yields. The company specializes in creating next-generation biopesticides derived from natural microorganisms, which serve as sustainable alternatives to traditional chemical pesticides facing regulatory challenges. Additionally, Aphea.Bio produces biostimulants that promote crop growth by enhancing nutrient uptake from the soil. Utilizing proprietary technologies, the company is dedicated to discovering new biocontrol and biostimulant products that help farmers sustainably manage fungal diseases, pests, and weeds, ultimately improving crop productivity and environmental health.

OCTIMET oncology’s overall strategy is to advance the development of discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy.

Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments to address various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technology aimed at improving the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular seeks to enhance therapeutic outcomes while minimizing side effects and reducing the frequency of treatments, thereby offering patients effective and life-changing solutions for their unmet medical needs.

Orionis Biosciences is a biotechnology company focused on early-stage drug discovery and development, particularly targeting oncology and immunotherapies. Headquartered in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes a range of innovative technologies to create conditionally active drug modalities aimed at treating diseases with significant unmet medical needs. By inducing molecular proximity and cooperativity, Orionis enhances drug potency and precision, allowing for novel target access. Their approach facilitates the development of a diverse pipeline of drug candidates, including therapies that engage both adaptive and innate immune systems. The company collaborates with strategic partners, including VIB in Belgium, and is supported by a team of seasoned entrepreneurs and scientists, as well as a transatlantic network of investors.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.